Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196
Want to see HK:2196 full AI Analyst Report?
Top Page
Shanghai Fosun Pharmaceutical (Group) Co
(2196)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$20.50
▲(4.43% Upside)
Action:ReiteratedDate:04/30/26
The score is driven primarily by improving fundamentals (strong TTM revenue rebound and steady profitability) but held back by weak cash conversion and only average returns with moderate leverage. Technical indicators are neutral-to-soft with the stock trading below key longer-term moving averages, while valuation looks fair with a moderate P/E and a modest dividend yield.
Positive Factors
Strong revenue rebound
A 158.4% TTM revenue rebound signals restored top-line momentum across the group's pharma manufacturing, distribution and services. Sustained revenue recovery supports operational scale, funds R&D and commercialization, and improves medium-term competitive positioning if trends persist.
Negative Factors
Weak cash conversion
Free cash flow at only ~24% of net income shows earnings are not efficiently converting to cash. This raises execution risk: larger working-capital needs, capex or unexpected costs could strain liquidity and limit ability to sustainably fund growth or reduce leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue rebound
A 158.4% TTM revenue rebound signals restored top-line momentum across the group's pharma manufacturing, distribution and services. Sustained revenue recovery supports operational scale, funds R&D and commercialization, and improves medium-term competitive positioning if trends persist.
Read all positive factors
Shanghai Fosun Pharmaceutical (Group) Co (2196) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$70.95B
Dividend Yield1.69%
Average Volume (3M)8.63M
Price to Earnings (P/E)14.2
Beta (1Y)1.11
Revenue Growth1.52%
EPS Growth22.54%
CountryHK
Employees40,557
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.38
Shares Outstanding551,940,500
10 Day Avg. Volume5,166,409
30 Day Avg. Volume8,626,817
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$33.65Price Target Upside71.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.49
Revenue Forecast (FY)HK$43.44B
Shanghai Fosun Pharmaceutical (Group) Co Business Overview & Revenue Model
Company Description
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Hea...
How the Company Makes Money
Fosun Pharma generates revenue primarily through multiple healthcare value-chain businesses. (1) Pharmaceutical manufacturing: The company earns sales revenue from producing and selling pharmaceutical products to hospitals, pharmacies, distributor...
Shanghai Fosun Pharmaceutical (Group) Co Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
63
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.87B | 40.42B | 41.07B | 41.40B | 43.95B | 39.01B |
| Gross Profit | 21.10B | 20.16B | 19.70B | 19.68B | 20.78B | 18.78B |
| EBITDA | 4.71B | 6.16B | 8.60B | 7.55B | 7.87B | 8.70B |
| Net Income | 3.45B | 3.28B | 2.77B | 2.39B | 3.73B | 4.73B |
Balance Sheet | ||||||
| Total Assets | 122.97B | 120.07B | 117.46B | 113.47B | 107.16B | 93.29B |
| Cash, Cash Equivalents and Short-Term Investments | 15.29B | 15.78B | 16.12B | 15.58B | 17.17B | 14.55B |
| Total Debt | 31.86B | 36.66B | 31.70B | 30.28B | 30.25B | 24.25B |
| Total Liabilities | 59.30B | 58.24B | 57.53B | 56.85B | 53.05B | 44.92B |
| Stockholders Equity | 49.15B | 48.72B | 47.26B | 45.68B | 44.58B | 39.19B |
Cash Flow | ||||||
| Free Cash Flow | 731.79M | 764.78M | 66.79M | -1.92B | -1.67B | -1.02B |
| Operating Cash Flow | 4.06B | 5.21B | 4.48B | 3.41B | 4.22B | 3.95B |
| Investing Cash Flow | -3.04B | -2.15B | -3.61B | -3.82B | -4.06B | -3.86B |
| Financing Cash Flow | 451.96M | -3.24B | -1.00B | -1.34B | 4.43B | -831.28M |
Shanghai Fosun Pharmaceutical (Group) Co Technical Analysis
Positive
19.63
Price Trends
19.82
Positive
20.44
Negative
21.18
Negative
Market Momentum
0.19
Negative
53.47
Neutral
61.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2196, the sentiment is Positive. The current price of 19.63 is above the 20-day moving average (MA) of 19.61, below the 50-day MA of 19.82, and below the 200-day MA of 21.18, indicating a neutral trend. The MACD of 0.19 indicates Negative momentum. The RSI at 53.47 is Neutral, neither overbought nor oversold. The STOCH value of 61.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2196.
Shanghai Fosun Pharmaceutical (Group) Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$224.98B | 35.71 | 16.09% | 0.97% | 22.62% | 26.23% | |
72 Outperform | HK$30.45B | 9.36 | 13.95% | 4.09% | 1.48% | -1.55% | |
63 Neutral | HK$31.20B | 19.33 | 8.60% | 2.26% | 10.00% | -7.54% | |
61 Neutral | HK$32.98B | 6.37 | 7.91% | 2.95% | 4.66% | 20.77% | |
58 Neutral | HK$70.95B | 14.15 | 7.02% | 1.69% | 1.52% | 22.54% | |
56 Neutral | HK$40.18B | 3.39 | 7.89% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
19.11
5.40
39.37%
HK:0867
China Medical System Holdings
12.79
4.69
58.00%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.71
0.55
3.43%
HK:1513
Livzon Pharmaceutical Group
28.16
3.30
13.30%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.25
0.48
10.11%
HK:3692
Hansoh Pharmaceutical Group Company Limited
37.10
12.97
53.75%
Shanghai Fosun Pharmaceutical (Group) Co Corporate Events
Fosun Pharma Subsidiary Wins Approval for Sodium Nitroprusside Injection
Apr 30, 2026
Shanghai Fosun Pharmaceutical announced that its subsidiary Yaopharma Co., Ltd. has received approval from the National Medical Products Administration for the drug registration of Sodium Nitroprusside Injection. The product is indicated for hyper...
Fosun Pharma Files Unaudited First-Quarter 2026 Report in Line With Hong Kong Rules
Apr 28, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited first quarterly report for 2026, covering the three months ended 31 March 2026 and prepared under PRC Accounting Standards for Business Enterprises. The announcement, issue...
Fosun Pharma Subsidiary Wins NMPA Nod for Dual-Target CAR-T Trial
Apr 14, 2026
Shanghai Fosun Pharmaceutical’s subsidiary Fosun Kairos has received approval from China’s National Medical Products Administration to initiate Phase I/II clinical trials of FKC289 Injection. The investigational therapy will target pat...
Fosun Pharma Subsidiary Wins China Nod for Flurbiprofen Pain Injection
Apr 10, 2026
Shanghai Fosun Pharmaceutical said that its subsidiary Yaopharma Co. has received approval from China’s National Medical Products Administration to market Flurbiprofen Axetil Injection. The drug is a chemical injection product indicated for ...
Fosun Pharma Sets April Board Meeting to Approve First-Quarter 2026 Results
Apr 10, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has scheduled a board meeting for 28 April 2026 to review and approve the group’s first-quarter results for the period ended 31 March 2026. The company plans to publish these quarterly figures ...
Fosun Pharma Wins China Trial Nod for Teva-Partnered Cancer Drug FXB0871
Mar 31, 2026
Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has received approval from China’s National Medical Products Administration to begin clinical trials of FXB0871 for patients with locally...
Fosun Pharma Lifts 2025 Profit on Higher Margins and EBITDA
Mar 24, 2026
Shanghai Fosun Pharmaceutical reported solid full-year 2025 results, with revenue edging up to RMB 41.5 billion and gross profit improving on a higher gross margin of 49.88%. Net profit attributable to shareholders rose to RMB 3.37 billion, liftin...
Fosun Pharma Proposes 2025 Final Dividend and Details Tax Treatment for H-Share Investors
Mar 24, 2026
Shanghai Fosun Pharmaceutical has proposed a final ordinary cash dividend of RMB 0.39 per share for the financial year ended 31 December 2025, subject to shareholders’ approval. Key timetable details, including the ex-dividend date, record d...
Fosun Pharma Subsidiary Wins Approval for Sodium Thiosulfate Antidote Injection
Mar 20, 2026
Shanghai Fosun Pharmaceutical has announced that its subsidiary Chongqing Carelife Pharmaceutical has obtained National Medical Products Administration approval for Sodium Thiosulfate Injection. The drug, classified as a Category 3 chemical and ma...
Fosun Pharma Unit Wins China Trial Nod for Novel Alopecia Biotherapeutic
Mar 16, 2026
Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai MicroH Therapeutics, has received approval from China’s National Medical Products Administration to conduct a clinical trial of LBP-ShC4, a live biotherapeutic product for...
Fosun Pharma Wins NMPA Nod to Start Trials of New Blood Cancer Drug FXS0683
Mar 13, 2026
Shanghai Fosun Pharmaceutical said its subsidiary Shanghai Fosun Pharmaceutical Industrial Development has received approval from China’s National Medical Products Administration to begin clinical trials of FXS0683 tablets for hematological ...
Fosun Pharma Sets March 2026 Board Meeting to Approve 2025 Results and Dividend Plan
Mar 9, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has scheduled a board meeting for 24 March 2026 to review and approve the audited financial results of the company and its subsidiaries for the year ended 31 December 2025. The board will also consid...
Fosun Pharma Reports Strong Shareholder Turnout at 2026 Extraordinary Meetings
Feb 27, 2026
Shanghai Fosun Pharmaceutical has reported the poll results of its first extraordinary general meeting of 2026, along with separate class meetings for A and H shareholders held in Shanghai. The meetings saw participation from both share classes, w...
Fosun Pharma Wins CSRC Nod for Up to RMB6 Billion Tech Innovation Bonds
Feb 26, 2026
Shanghai Fosun Pharmaceutical has received approval from the China Securities Regulatory Commission to register a public issuance of up to RMB6 billion in Science and Technology Innovation Corporate Bonds targeted at professional investors in the ...
Fosun Pharma Wins NMPA Nod for New Lung Cancer Trial of Luvometinib
Feb 25, 2026
Shanghai Fosun Pharmaceutical said its subsidiary Shanghai Fosun Pharmaceutical Industrial Development has received approval from China’s National Medical Products Administration to conduct a clinical trial for an additional indication of it...
Fosun Pharma Subsidiary Wins NMPA Acceptance for New Anesthetic Drug
Feb 13, 2026
Shanghai Fosun Pharmaceutical said that its subsidiary Jinzhou Avanc Pharmaceutical has had its drug registration application for Moxetomidate Hydrochloride Injection accepted by China’s National Medical Products Administration. The class 1 ...
Fosun Pharma Subsidiary’s Cisplatin Injection Application Accepted by Chinese Regulator
Feb 13, 2026
Shanghai Fosun Pharmaceutical has disclosed that its subsidiary Jisimei (Wuhan) Pharmaceutical has had a drug registration application for a Cisplatin Injection accepted by China’s National Medical Products Administration. The chemotherapy p...
Fosun Pharma Subsidiary Wins Acceptance of Tetracaine Gel Registration in China
Feb 10, 2026
Shanghai Fosun Pharmaceutical announced that the National Medical Products Administration has accepted a drug registration application filed by its subsidiary Shanghai Zhaohui Pharmaceutical for Tetracaine Hydrochloride Gel, a percutaneous local a...
Fosun Pharma Wins Priority Review in China for New Luvometinib Indication
Feb 5, 2026
Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, has had a new drug registration application for Luvometinib Tablets (brand name 复迈宁) accepted b...
Fosun Pharma Subsidiary’s Cyclophosphamide Injection Application Accepted by Chinese Regulator
Feb 5, 2026
Shanghai Fosun Pharmaceutical announced that the National Medical Products Administration has accepted a drug registration application submitted by its subsidiary Jisimei (Wuhan) Pharmaceutical for Cyclophosphamide Injection, a chemical drug indep...
Fosun Pharma Calls 2026 EGM to Advance Spin-off and Hong Kong Listing of Fosun Adgenvax
Feb 4, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has called its first extraordinary general meeting of 2026 for 27 February in Shanghai, seeking shareholder approval for the proposed spin-off and separate listing of its subsidiary Fosun Adgenvax on...
Fosun Pharma Calls H-Share Vote on Fosun Adgenvax Spin-Off Entitlements
Feb 4, 2026
The company has convened its 2026 first class meeting of H shareholders for 27 February in Shanghai to vote on granting H-share investors assured entitlements tied to the planned spin-off and Hong Kong listing of subsidiary Fosun Adgenvax, undersc...
Shanghai Fosun Pharma Completes First Tranche of 2026 Innovation Bonds
Feb 3, 2026
Shanghai Fosun Pharmaceutical has completed the issuance of its first tranche of 2026 scientific and technological innovation bonds under a previously approved RMB4 billion medium-term note registration, continuing its strategy of tapping China...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.